Industry
Biotechnology
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 10:50 am
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 11:02 am
Portfolio Pulse from Benzinga Newsdesk
August 02, 2024 | 7:06 am
Portfolio Pulse from Avi Kapoor
July 29, 2024 | 5:19 pm
Portfolio Pulse from Benzinga Newsdesk
July 02, 2024 | 8:09 pm
Portfolio Pulse from Benzinga Newsdesk
June 18, 2024 | 11:18 am
Portfolio Pulse from Benzinga Newsdesk
June 18, 2024 | 10:16 am
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 11:23 am
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 11:05 am
Portfolio Pulse from Benzinga Newsdesk
May 01, 2024 | 10:27 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.